UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lung cancer: current therapies and new targeted treatments

The Lancet (British edition), 2017-01, Vol.389 (10066), p.299-311

2017

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Cancer, 2020-11, Vol.126 (22), p.4867-4877

2020

Volltextzugriff (PDF)

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Journal of thoracic oncology, 2020-03, Vol.15 (3), p.404-415

2020

Volltextzugriff (PDF)

Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options

Journal of clinical oncology, 2022-02, Vol.40 (6), p.671-680

2022

Volltextzugriff (PDF)

Targeted therapy for lung cancer: Beyond EGFR and ALK

Cancer, 2023-06, Vol.129 (12), p.1803-1820

2023

Volltextzugriff (PDF)

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Journal of thoracic oncology, 2022-02, Vol.17 (2), p.289-308

2022

Volltextzugriff (PDF)

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The lancet oncology, 2021-07, Vol.22 (7), p.959-969

2021

Volltextzugriff (PDF)

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2895-2902

2013

Volltextzugriff (PDF)

Targeting EGFR in Lung Cancer: Current Standards and Developments

Drugs (New York, N.Y.), 2018-06, Vol.78 (9), p.893-911

2018

Volltextzugriff (PDF)

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

Cancer, 2022-05, Vol.128 (9), p.1801-1811

2022

Volltextzugriff (PDF)

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

The lancet oncology, 2024-04, Vol.25 (4), p.439-454

2024

Volltextzugriff (PDF)

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2012-09, Vol.30 (25), p.3084-3092

2012

Volltextzugriff (PDF)

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2490-2498

2017

Volltextzugriff (PDF)

Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC

Journal of cellular and molecular medicine, 2014-08, Vol.18 (8), p.1519-1539

2014

Volltextzugriff (PDF)

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

The lancet oncology, 2011-08, Vol.12 (8), p.795-805

2011

Volltextzugriff (PDF)

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma

International journal of molecular sciences, 2021-03, Vol.22 (5), p.2538

2021

Volltextzugriff (PDF)

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2516-2522

2009

Volltextzugriff (PDF)

Inhibition of HSP90 molecular chaperones: moving into the clinic

The lancet oncology, 2013-08, Vol.14 (9), p.e358-e369

2013

Volltextzugriff (PDF)

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2022-04, Vol.40 (12), p.1301-1311

2022

Volltextzugriff (PDF)

Current Challenges in Cancer Treatment

Clinical therapeutics, 2016-07, Vol.38 (7), p.1551-1566

2016

Volltextzugriff (PDF)

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

International journal of clinical oncology, 2021-06, Vol.26 (6), p.1073-1082

2021

Volltextzugriff (PDF)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Cancer medicine (Malden, MA), 2021-09, Vol.10 (17), p.5878-5888

2021

Volltextzugriff (PDF)

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

Journal of clinical oncology, 2023-02, Vol.41 (6), p.1200-1212

2023

Volltextzugriff (PDF)

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Journal of clinical oncology, 2019-04, Vol.37 (12), p.992-1000

2019

Volltextzugriff (PDF)

1 – 25 von 720

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(678)
Mit Volltextzugriff
(659)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(378)
Life Sciences & Biomedicine
(366)
Oncology
(306)
Humans
(302)
Female
(155)
Male
(154)
Lung Neoplasms - Drug Therapy
(151)
Middle Aged
(136)
Aged
(132)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(131)
Lung Cancer
(122)
Adult
(101)
Lung Neoplasms - Pathology
(100)
Tumors
(97)
Chemotherapy
(92)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(89)
Mutation
(77)
Respiratory System
(76)
Immunotherapy
(73)
Lung Neoplasms - Genetics
(73)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Lung cancer: current therapies and new targeted treatments

Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials

Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial

Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options

Targeted therapy for lung cancer: Beyond EGFR and ALK

First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

Targeting EGFR in Lung Cancer: Current Standards and Developments

RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial

Pooled analysis of clinical outcome for EGFR TKI‐treated patients with EGFR mutation‐positive NSCLC

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma

Phase II Study of the Anti–Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non–Small-Cell Lung Cancer

Inhibition of HSP90 molecular chaperones: moving into the clinic

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

Current Challenges in Cancer Treatment

First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Suchergebnisse filtern